Abstract: To study the efficacy of specific active immunotherapy in the treatment of chronic hepatitis B. 60 patients diagnosed as chronic hepatitis B With normal liver functiion after being treated with conventional therapy were randomly assigned into two groups (treated group and control group) . The treated group including 30 cases were treated with specific active immunotherapy for 4 months and the control group received a conventional treatment for 4 months. 4 of the 30 cases in the treated group were seroconverted from positive to negative against HBsAg, while none of the 30 cases in the control group became HBeAg negative. 9 of the 30 cases in the treated group became negative HBeAg, contrastively, only one case in the control group became HBeAg negative (P<0 05) . Moreover, the HBVDNA copies was markedly reduced from (0.03±0.02×10 5) copies/ml to (0.007±0.003×10 5) copies/ml in the treated group as compared with the control group (t=5.48) . From this preliminary clinical study, it is suggested that the specific active immunotherapy might has a benificial effect on chronic hepatitis B cases.